Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus

American Journal of the Medical Sciences

Volumn 348, Issue 2, 2014, Pages 156-161

  Ouyang, Han ^a   Shi, Yong Bing ^a   Liu, Zhi Chun ^a,b   Wang, Zhi ^a   Feng, Sheng ^a   Kong, Shu Min ^a   Lu, Ying ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Department of Rheumatology ^*  (China)

Author keywords

EBI3; Glucocorticoid; Interleukin 35; Lupus erythematosus; Systemic

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; EPSTEIN BARR VIRUS INDUCED GENE PROTEIN 3; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 35; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; SM ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANEMIA; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HOSPITAL PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LABORATORY TEST; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; PROTEIN BLOOD LEVEL; PROTEINURIA; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 84905019371     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000215     Document Type: Article

References (25)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-9.
2. Herrmann M, Voll RE, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000;9:424-6.
3. Pan HF, Ye DQ, Li XP. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4:352-3.
4. Li ZJ, Li YJ, Huang LH, et al. Expression of interleukin-12 and its signaling molecules in peripheral blood mononuclear cells in systemic lupus erythematosus patients. Chin Med J (Engl) 2002;115:846-50.
5. Ouyang H, Shi YB, Su N, et al. Abnormality and significance of IL-9 and CD4+IL-9+T-cells in peripheral blood of patients with systemic lupus erythematosus [in Chinese]. Zhonghua Yi Xue Za Zhi 2013;93: 99-103.
6. Chen XW, Zhang Z, Jiang LM, et al. Elevated interleukin-13 in patients with active lupus nephritis. Chin Med J (Engl) 2001;114: 1022-5.
7. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997;94:12041-6.
8. Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996;70:1143-53.
9. Niedobitek G, Päzolt D, Teichmann M, et al. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002;198: 310-6.
10. Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-9.
11. Yang J, Yang M, Htut TM, et al. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgammat. Eur J Immunol 2008;38:1204-14.
12. Nieuwenhuis EE, NeurathMF, Corazza N, et al. Disruption of T helper 2-immune responses in Epstien-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci U S A 2002;99:16951-6.
13. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450: 566-9.
14. Whitehead GS, Wilson RH, Nakano K, et al. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012;129:207-15.
15. Bardel E, Larousserie F, Charlot-Rabiega P, et al. Human CD4+CD25 +Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008;181:6898-905.
16. Allan SE, Song-Zhao GX, Abraham T, et al. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008;38:3282-9.
17. Chaturvedi V, Collison LW, Guy CS, et al. Cutting edge. Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011;186:6661-6.
18. Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11:1093-101.
19. Kochetkova I, Golden S, Holderness K, et al. IL-35 stimulation of CD39+regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010;184:7144-53.
20. Tan EM, Cohen AS, Fries JF, et al. The 1982 revisedcriteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
21. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
22. Zandian M, Mott KR, Allen SJ, et al. Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2. Gene Ther 2011;18:734-42.
23. Huang CH, Loo EX, Kuo IC, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011;187:462-71.
24. Cai XY, Luo M, Lin XJ, et al. Expression and significance of Th17 and Treg cells in peripheral blood of patients with systemic lupus erythematosus [in Chinese]. Zhonghua Yi Xue Za Zhi 2012;92:460-3.
25. Suarez A, Lopez P, Comez J, et al. Enrichment of CD4+ CD25 high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006;65:1512-7.